THANK YOU FOR SUBSCRIBING
Bridge has been improving its research and drug discovery engines by utilizing a shared database system to manage scientific materials efficiently.
FREMONT, CA: Bridge Biotherapeutics, Inc., a publicly listed biotech firm focused on drug discovery and development, announced that CDD Vault incorporated into its internal collaboration workflow. CDD Vault, a hosted informatics platform for managing, sharing, and analyzing scientific research data globally, is projected to significantly speed up and streamline the company's cross-border research and discovery efforts.
Bridge Biotherapeutics, focusing on expanding its research and development pipeline in the areas of inflammation, pulmonology, and oncology, and advancing clinical channels like a Pellino-1 inhibitor for ulcerative colitis (UC), BBT-401,BBT-877, an Autotaxin inhibitor with the ability to treat fibrotic diseases. Like idiopathic pulmonary fibrosis (IPF) and BBT-176, an EGFR tyrosine kinase inhibitor of the fourth generation for non-small cell lung cancer (NSCLC) a novel anti-inflammatory drug. With multiple integrated research work getting carried out in different labs and geographies, a solution that can share, manage, store, and analyze large amounts of data in real-time is becoming increasingly crucial while accommodating scientific diagrams, chemical structures, biological data, and more.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Bridge Biotherapeutics will use CDD Vault, a secure web interface software platform for managing chemical and biological data in a collaborative environment, to support its research and drug discovery activities. It allows its scientists, medicinal chemists, and other professionals working on drug discovery and development projects worldwide to collaborate seamlessly. The system's main components are Activity & Registration, Visualization, Inventory, and the Electronic Lab Notebook (ELN).
"As we pursue the discovery of novel compounds through internal collaboration and with external partners while being unconstrained by our diverse geographical locations, we have intended for our activities to be supported by a robust and secure compound management platform. We have found CDD to fulfil our needs through its CDD Vault which offers proven functionalities that are seamlessly integrated," said Dr. Chris Kim, head of the Boson Discovery Center at Bridge Biotherapeutics, "We are excited to have CDD as our partner as we continue to rapidly advance our research and discovery programs."
"We are delighted to welcome Bridge Biotherapeutics to the ever-expanding CDD Vault network of users. It is exciting to support this global, entrepreneurially operated, and highly innovative biotech company in their quest for new drug candidates," said Dr. Barry Bunin, CEO of Collaborative Drug Discovery, "We continue to increase CDD Vault's footprint in the Asia Pacific and Bridge Biotherapeutics is a testament to the trust our platform has received in the Korean biotech industry."
More in News